Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Cash from Operations: 2018-2024

Historic Cash from Operations for Black Diamond Therapeutics (BDTX) over the last 7 years, with Dec 2024 value amounting to -$62.3 million.

  • Black Diamond Therapeutics' Cash from Operations fell 52.44% to -$24.0 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$100.1 million, marking a year-over-year decrease of 92.05%. This contributed to the annual value of -$62.3 million for FY2024, which is 6.62% up from last year.
  • As of FY2024, Black Diamond Therapeutics' Cash from Operations stood at -$62.3 million, which was up 6.62% from -$66.7 million recorded in FY2023.
  • Black Diamond Therapeutics' Cash from Operations' 5-year high stood at -$52.1 million during FY2020, with a 5-year trough of -$100.1 million in FY2021.
  • Over the past 3 years, Black Diamond Therapeutics' median Cash from Operations value was -$66.7 million (recorded in 2023), while the average stood at -$71.4 million.
  • Per our database at Business Quant, Black Diamond Therapeutics' Cash from Operations crashed by 111.34% in 2020 and then grew by 21.59% in 2023.
  • Yearly analysis of 5 years shows Black Diamond Therapeutics' Cash from Operations stood at -$52.1 million in 2020, then plummeted by 92.05% to -$100.1 million in 2021, then grew by 15.04% to -$85.1 million in 2022, then grew by 21.59% to -$66.7 million in 2023, then increased by 6.62% to -$62.3 million in 2024.